American Society of Plastic Surgeons
For Medical Professionals

MRI Is Most Accurate Test for Detecting Ruptured Silicone Breast Implants
But Ultrasound Still Plays a Role in Follow-Up After Breast Reconstruction, Reports Plastic and Reconstructive Surgery

PHILADELPHIA — Magnetic resonance imaging (MRI) has higher accuracy than ultrasound in diagnosing ruptured silicone implants after breast reconstruction, reports a study in the July issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Ultrasound is still the most appropriate test for screening and follow-up for women with implant-based breast reconstruction after mastectomy, according to the report by Dr. Mario Rietjens and colleagues of the European Institute of Oncology, Milan. But the new findings suggest that the plastic surgeon should use MRI to make a definitive diagnosis of implant rupture, before performing repeat breast surgery.

MRI vs Ultrasound for Diagnosis of Breast Implant Rupture

The researchers compared the accuracy of MRI versus ultrasound for detecting ruptured implants. They study included 102 women who had received silicone gel implants for breast reconstruction after mastectomy for breast cancer. A median of five years later, the women were undergoing repeat surgery to change the implant for cosmetic reasons. At that time, none of the patients had symptoms of implant rupture or other problems.

Before surgery, all patients underwent both MRI and ultrasound scanning. The researchers compared the two imaging methods for their ability to detect ruptured silicone implants, as confirmed at repeat surgery.

At surgery, 28 percent of the women were found to have implant rupture. Ruptured implants appeared to be more common five years or longer after breast reconstruction.

Overall, MRI was 94 percent accurate in detecting ruptured implants, compared to 72 percent accuracy for ultrasound. Magnetic resonance imaging also had a lower "false-negative" rate: five percent, compared to nine percent with ultrasound. Thus MRI was less likely to miss a ruptured implant, compared to ultrasound.

However, both tests performed well in correctly indicating when implants weren't ruptured. The "negative predictive value" was 94 percent with MRI and 85 percent with ultrasound.

Implications for Screening and Diagnosis after Breast Reconstruction

Implants are widely used for breast reconstruction after mastectomy. Implant rupture is an important complication, resulting in cosmetic problems and requiring further surgery. The need for additional surgery increases the risk of other problems, such as hardening (contracture) of the capsule around the implant, scarring, and pain.

The true rate of ruptured implants is unknown; they can't be reliably detected based on symptoms or physical examination. Studies of different imaging options for detecting ruptured implants have reported varying results. The new study of women undergoing implant removal for cosmetic reasons provides an opportunity to compare MRI versus ultrasound for detection of ruptured implants.

"Our results show that MRI performs better than ultrasound for diagnosis of breast implant rupture, " Dr. Rietjens and coauthors write. They identify some MRI findings specifically associated with the presence of ruptured implants, and suggest that accuracy may be further increased by standardizing MRI criteria.

Where available, MRI should be regarded as the preferred imaging test for women with suspected implant rupture, according to the authors. However, if MRI is unavailable or can't be used, ultrasound is a useful alternative.

However, because of the higher cost of MRI, ultrasound is preferable as a routine follow-up test after implant-based breast reconstruction in women who are free of any symptoms, Dr. Rietjens and colleagues believe. If ultrasound suggests possible implant rupture, the diagnosis should be confirmed by MRI. Screening with MRI may be more appropriate after five years, when the rate of implant rupture is higher.

Plastic and Reconstructive Surgery is published by Lippincott Williams & Wilkins, part of Wolters Kluwer Health.

About Plastic and Reconstructive Surgery

For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPS

The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 8,000 member surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 93 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.


Patient Care Center